Case Studies

Diana M. Sobieraj, PharmD, and Craig I. Coleman, PharmD
Published Online: Monday, January 20, 2014
Follow Pharmacy_Times:
Case 1
MJ is a 44-year-old female who comes to the pharmacy to purchase a box of Oxytrol for Women. She states that she has been experiencing symptoms of urinary incontinence in which she “feels like I have to go but can’t control it,” and she feels embarrassed by the amount of times she has to go to the bathroom daily. Recently, she has had a few additional episodes of incontinence related to sneezing. She saw a commercial for Oxytrol on TV and thought she would try it before talking with her doctor. MJ denies any other significant medical history other than hypertension, which is well controlled by lisinopril 40 mg daily. She has no known allergies.
As the available pharmacist, do you believe MJ is a candidate for OTC Oxytrol for Women?

Case 2
BT is a 65-year-old male with hypertension, type 2 diabetes mellitus (DM), osteoarthritis, and benign prostatic hypertrophy. He had a myocardial infarction 2 years ago and has been taking Lipitor 80 mg daily ever since. BT has tolerated therapy very well and has no complaints of muscle aches and pains. His liver function test results have always been within normal limits. He expresses concern about the strength of his statin therapy and questions the need for such a high dose.
Is high-dose statin therapy appropriate for BT according to the new American College of Cardiology–American Heart Association guidelines for the treatment of high cholesterol?

Dr. Sobieraj is assistant professor of pharmacy practice, and Dr. Coleman is professor of pharmacy practice as well as codirector and methods-chief, at Hartford Hospital Evidence-Based Practice Center at the University of Connecticut School of Pharmacy.


Related Articles
In light of misrepresented statistics and overstated fears about statin-related adverse events, here are 3 of the biggest myths your patients may have heard about these life-saving medications—and the facts
Sanofi has announced the FDA approval of its insulin glargine injection (Toujeo), a once-daily long-acting basal insulin, for the improvement of glycemic control in adults with type 1 and type 2 diabetes.
Novo Nordisk has positive results from a completed phase 2 trial on the oral formulation of its investigational, long-acting human glucagon-like peptide-1 analogue.
Many patients with non-alcoholic fatty liver disease also have low vitamin D levels.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$